Regarding DCR, this investigation revealed that TMPs + sorafenib co-treatment was better than TMP + other VEGFR-TKIs, implying that TMPs may synergistically potentiate the anti-tumor effects of sorafenib/ lenvatinib against middle-advanced PLC. The gene discussed is KDR; the disease is neoplasm.